The Rising Geriatric Population Drives The Filgrastim Biosimilars Market

Filgrastim Biosimilars Market Opportunities And Strategies -  Forecast To 2030

Filgrastim Biosimilars Market Opportunities And Strategies – Global Forecast To 2030

The Business Research Company’s Filgrastim Biosimilars Market Report – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, July 1, 2021 /EINPresswire.com/ — The population profile of most countries is becoming older, thus driving the demand for biopharmaceuticals such as filgrastim biosimilars to treat side effects caused by the treatment of various chronic diseases including cancer. The proportion of people above the age of 65 years increased globally and age-related chronic ailments also increased. For example, the percentage of seniors is expected to grow from 28% in 2019 to 38% in 2050 in Japan. The increase in the aging population has expanded the patient pool of many chronic diseases such as cancer. People suffering from these diseases are expected to be more vulnerable to chronic diseases, thus significantly impacting market growth during this period.

The global filgrastim biosimilars market is expected to grow from $0.72 billion in 2020 to $0.77 billion in 2021 at a compound annual growth rate (CAGR) of 6.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The filgrastim biosimilars market is expected to reach $1.04 billion in 2025 at a CAGR of 8%.

Read More On The Global Filgrastim Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilars-market

The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. Only goods and services traded between entities or sold to end consumers are included.

Major players in the filgrastim biosimilars industry are Cadila Pharmaceuticals, Dr. Reddy’s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy’s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon, and Aryogen Biopharma.
The filgrastim biosimilars market report is segmented by application into oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, others and by distribution channels into hospital pharmacy, retail pharmacy, online pharmacy, by type of manufacturing into in-house manufacturing, contract manufacturing organization.

Filgrastim Biosimilars Market – By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030 is one of a series of new reports from The Business Research Company that provides filgrastim biosimilars global market overview, forecast filgrastim biosimilars global market size and growth for the whole market, filgrastim biosimilars global market segments, and geographies, filgrastim biosimilars global market trends, filgrastim biosimilars global market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Filgrastim Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3426&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Pegfilgrastim Biosimilars Market – By Application (Chemotherapy Induced Neutropenia, Transplantation, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order/Online Pharmacies), And By Region, Opportunities And Strategies – Global Pegfilgrastim Biosimilars Market Forecast To 2030
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market

Biosimilar Hormones Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/biosimilar-hormones-global-market-report-2020-30-covid-19-growth-and-change

Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/rituximab-biosimilars-global-market-report-2020-30-covid-19-growth-and-change

Interested to know more about The Business Research Company?

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The Business Research Company
Email: info@tbrc.info
Follow us on LinkedIn: https://bit.ly/3b7850r
Follow us on Twitter: https://bit.ly/3b1rmjS
Check out our Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn

Leave a Reply

Your email address will not be published.